Day One (13th May 2025) - CET/CEST (Cent Europe Summer, GMT+2)
- Shan-Hua Chung - Principal Scientist and Matrix Lead in Cell Technologies, Roche
- David Öling - Director, Molecular Biology and Recombinant Protein Production, AstraZeneca
- Moritz Schmidt - Head of Laboratory Molecular Biology, Boehringer Ingelheim
- Lasse Ebdrup Pedersen - Associate Professor, The Technical University of Denmark
In this presentation we will discuss key aspects related to rAAV production systems' scalability, addressing challenges and future directions for product characterization. Our research lies in improving stable cell line-based production systems for rAAV production. How to optimise the cell line generation process and improve the cell host by CRISPR-Cas9 genetic screen and single cell RNA-seq approaches will be discussed.
- Jose Miguel Escandell Planells - Principal Scientist, iBET - Instituto de Biologia Experimental e Tecnológica
Recombinant protein expression is a highly regulated process consisting of transcription, translation, and protein folding. CHO-based expression often stays challenging for artificial therapeutic proteins, like Bispecific T-cell Engagers (BiTE®) due to reduced productivity compared to monoclonal antibodies. A differentiated insight into the evaluation of expression steps will be given, as well as strategies to find bottlenecks.
- Benedikt Greck - Doctoral Student, Platformization of Complex Molecules, Amgen